Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates

DUBLIN, Ireland, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today reported financial results for the second quarter and first six months of 2020. In addition, the Company provided an update on its R&D programs.

Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update

DUBLIN, Ireland, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease was selected as an oral Top Abstract presentation at the upcoming virtual International Congress of Parkinson’s Disease and Movement Disorders Society (MDS). Prasinezumab is the focus of a worldwide collaboration between Prothena and Roche. In addition, Wagner Zago, PhD, Prothena’s Chief Scientific Officer, will participate in a Science of Industry session during MDS.

Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders

DUBLIN, Ireland, July  30, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it will report its second quarter and first six months of 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets.

Prothena to Report Second Quarter 2020 Financial Results on August 6

Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session

Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

DUBLIN, Ireland, April  22, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease. As updated by Roche during its 1Q20 earnings  announcement , the study did not meet the primary objective, but showed signals of efficacy. These signals were observed on multiple prespecified secondary and exploratory clinical endpoints. Roche has begun further clinical development planning activities and is evaluating the data from Part 1 of the PASADENA study to determine next steps. Based on ongoing evaluation of the data, including potential discussions with health authorities, a further update on prasinezumab is expected later this year.

Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

DUBLIN, Ireland, March  31, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be presented by Roche in an oral presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD Focus Meeting (AAT-AD/PD), to be held virtually on April 2-5, 2020. Prasinezumab, a monoclonal antibody under development for the potential treatment of Parkinson's disease, is the focus of a worldwide collaboration between Prothena and Roche.

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?

Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.

Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

Prothena Corporation (PRTA) CEO Gene Kinney on Q4 2019 Results - Earnings Call Transcript

Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Prothena (PRTA) Stock

DUBLIN, Ireland, Dec.  05, 2019  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors.

Prothena Announces Appointment of Oleg Nodelman to its Board of Directors

Why Is Prothena (PRTA) Up 36.1% Since Last Earnings Report?

Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.

Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3

Prothena (PRTA) delivered earnings and revenue surprises of 9.26% and 36.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q3 Loss, Tops Revenue Estimates

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Acacia Research

Blueknight Energy Partners, L.P.

HC2 Holdings

Finding stocks with a negative enterprise value is an excellent way to find deep value

4 Negative Enterprise Value Stocks

Why Is Prothena (PRTA) Down 8.9% Since Last Earnings Report?

Shares have fallen by 38% over the past year.

Prothena: Trading Below Cash, Key Clinical Readouts In Coming Year

Will Prothena (PRTA) Report Negative Q2 Earnings? What You Should Know

Prothena (PRTA) Down 14.1% Since Last Earnings Report: Can It Rebound?

Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.

News for Prothena Stock (PRTA)